Monte Rosa Therapeutics Income Statement (2020-2026) | GLUE

Income Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
1.06M4.70M9.22M60.65M84.93M23.19M150.00M2.78M4.30M
Operating items
Research & Development (Quarter)
14.64M15.12M18.13M17.91M20.94M21.34M24.87M26.75M29.08M28.31M27.14M27.03M28.05M27.62M38.87M32.19M30.65M36.68M41.98M44.07M
Selling, General & Administrative (Quarter)
3.49M4.75M5.26M6.39M6.29M7.02M7.62M7.50M8.14M8.66M7.73M8.98M9.28M8.13M8.78M8.70M8.10M9.06M10.52M10.18M
Restructuring Costs (Quarter)
6.81M7.62M7.46M7.75M8.23M7.85M8.57M9.21M10.11M
Other Operating Expenses (Quarter)
0.12M-0.02M0.02M0.06M
Operating Expenses (Quarter)
18.12M19.87M23.39M24.30M27.23M28.36M32.49M34.26M37.22M36.97M34.86M36.01M37.34M35.74M47.64M40.89M38.75M45.74M52.50M54.24M
Operating Income (Quarter)
-18.12M-19.87M-23.39M-24.30M-27.23M-28.36M-32.49M-34.26M-37.22M-36.97M-34.86M-34.95M-32.64M-26.53M13.00M44.04M-15.55M-32.98M-3.81M-50.03M
EBIT (Quarter)
-18.12M-19.87M-23.39M-24.30M-27.23M-28.36M-32.49M-34.26M-37.22M-36.97M-34.86M-34.95M-32.64M-26.53M13.00M44.04M-15.55M-32.98M-3.81M-50.03M
Non-operating items
Non Operating Investment Income (Quarter)
-0.13M
Interest & Investment Income (Quarter)
0.01M0.01M0.01M0.15M0.63M1.00M1.99M2.44M2.30M2.23M2.37M2.44M2.64M2.89M2.60M3.44M3.07M2.75M3.69M5.59M
Other Non Operating Income (Quarter)
-0.30M0.02M-0.07M0.10M0.13M0.06M-0.28M-0.09M-0.09M0.03M-0.78M0.62M-0.05M-0.15M0.00M0.17M1.39M-0.03M-0.05M-0.01M
Non Operating Income (Quarter)
-0.28M0.03M-0.05M0.37M0.76M1.04M1.71M2.22M2.23M2.25M1.59M3.06M2.58M2.74M2.60M3.67M4.46M2.72M3.64M5.58M
Net income details
EBT (Quarter)
-18.11M-19.86M-23.37M-24.15M-26.47M-27.32M-30.78M-32.04M-34.99M-34.71M-33.27M-31.89M-30.06M-23.79M15.60M47.71M-11.10M-30.26M-29.43M-44.45M
Tax Provisions (Quarter)
0.19M0.17M-0.02M0.08M0.25M0.07M2.16M0.82M1.20M-3.18M0.06M0.05M
Profit After Tax (Quarter)
-18.41M-19.84M-23.48M-23.93M-26.47M-27.32M-30.80M-32.04M-35.18M-34.88M-33.30M-31.97M-30.31M-23.86M13.44M46.88M-12.29M-27.08M-46.11M-44.50M
Income from Continuing Operations (Quarter)
-18.11M-19.86M-23.37M-24.15M-26.47M-27.32M-30.78M-32.04M-35.18M-34.88M-33.25M-31.97M-30.31M-23.86M13.44M46.88M-12.29M-27.08M-29.49M-44.50M
Consolidated Net Income (Quarter)
-18.11M-19.86M-23.37M-24.15M-26.47M-27.32M-30.78M-32.04M-35.18M-34.88M-33.25M-31.97M-30.31M-23.86M13.44M46.88M-12.29M-27.08M-29.49M-44.50M
Income towards Parent Company (Quarter)
-18.11M-19.86M-23.37M-24.15M-26.47M-27.32M-30.78M-32.04M-35.18M-34.88M-33.25M-31.97M-30.31M-23.86M13.44M46.88M-12.29M-27.08M-29.49M-44.50M
Net Income towards Common Stockholders (Quarter)
-18.11M-19.86M-23.37M-24.15M-26.47M-27.32M-30.78M-32.04M-35.18M-34.88M-33.25M-31.97M-30.31M-23.86M13.44M46.88M-12.29M-27.08M-29.49M-44.50M
Additional items
EPS (Basic) (Quarter)
-3.63-0.43-0.11-0.51-0.57-0.58-0.63-0.65-0.71-0.70-0.57-0.53-0.43-0.290.230.57-0.15-0.33-0.55-0.45
EPS (Weighted Average and Diluted) (Quarter)
-3.63-0.43-0.11-0.51-0.57-0.58-0.63-0.65-0.71-0.70-0.57-0.53-0.43-0.290.230.57-0.15-0.33-0.55-0.45
Shares Outstanding (Weighted Average) (Quarter)
5.07M45.99M25.00M46.60M46.67M46.67M47.23M49.35M49.39M49.81M51.40M60.16M65.70M82.01M73.91M82.15M82.17M82.25M83.07M99.88M
Shares Outstanding (Diluted Average) (Quarter)
3.40M45.99M25.00M46.60M46.67M46.73M47.23M49.35M49.39M49.81M51.40M60.16M65.70M82.01M73.91M82.96M82.19M82.94M83.07M99.88M
EBITDA (Quarter)
-18.90M-20.37M-23.51M-24.04M-26.79M-27.46M-29.93M-31.68M-35.42M-34.70M-34.52M-31.94M-30.29M-23.51M12.40M46.91M-12.34M-26.95M-46.72M-45.42M
Tax Rate (Quarter)
-0.54%-0.49%0.07%-0.26%-0.84%-0.30%13.87%1.72%-10.81%10.50%-0.20%-0.12%